Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING‐Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy
Arthritis & Rheumatology · 2025-08 · 77 (8) · 1087-1091
DOI: 10.1002/art.43145 ↗Kurz gefasst
Fallbericht in der Zeitschrift Arthritis & Rheumatology, online erschienen am 22.04.2025. Verfasst von Sara Alehashemi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Translational Autoinflammatory Diseases Section, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Intramural NIH HHS, Intramural Research Program at the National Institute of Allergy Immunology and Infectious Diseases of the National Institutes of Health.
Abstract (Originalsprache)
Objective
The objective was to report the safety and efficacy of an anti‐IFNAR1 antibody (anifrolumab) in a patient with STING‐associated vasculopathy with onset in infancy (SAVI) who presented with vasculitic ulcers and systemic inflammation refractory to JAK inhibition (JAKi) and to the interferon‐β–neutralizing monoclonal antibody dazukibart.
Methods
A patient with SAVI and a de novo STING1 p.(Asn154Ser) mutation, a known pathogenic variant, and uncontrolled disease received 21 doses of dazukibart under a compassionate use investigational new drug protocol, which was followed by treatment with the anti‐IFNAR1 antibody anifrolumab. Clinical and laboratory parameters, including wound healing, whole‐blood type I interferon (IFN I) signature, and safety markers were closely monitored throughout both treatment periods.
Results
Despite initial reductions in C‐reactive protein levels and IFN I scores following dazukibart administration, the patient experienced rebound inflammation and recurrent vasculitic lesions. Dazukibart dose adjustments failed to sustainably control IFN I signaling. Subsequent combination therapy of baricitinib and tocilizumab proved partially effective. Treatment with anifrolumab, an IFNAR1 blocker, in conjunction with tocilizumab led to sustained suppression of IFN I scores, allowed discontinuation of JAKi, and resulted in significant improvement in vasculitic wounds.
Conclusion
This case underscores the challenges in treating patients with SAVI and highlights the utility of IFN I scores as a theragnostic biomarker. Although high‐dose JAKi and dazukibart failed to achieve sustained control of IFN I signaling, treatment with anifrolumab durably suppressed IFN scores and demonstrated promising efficacy, which allows for the investigation of the role of IFN I signaling in the disease pathogenesis of SAVI and other interferonopathies in future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Autoinflammatory Diseases Section, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland.
- Bergisches Rheuma-Zentrum, Wuppertal, Germany.
- Clinical Pharmacology Program, National Cancer Institute, NIH, Bethesda, Maryland.
- Frederick National Laboratory for Cancer Research, Frederick, Maryland.
- Pharmacy Department, National Institutes of Health Clinical Center, NIH, Bethesda, Maryland.
ORCID-Profile: Kip Friend
Förderung
- NCI NIH HHS
- Intramural NIH HHS
- Intramural Research Program at the National Institute of Allergy Immunology and Infectious Diseases of the National Institutes of Health
- National Cancer Institute
Zitieren
APA
Alehashemi, S., Buehring, B., de Jesus, A. A., Gaurav, S., Rastegar, A., Baumgardner, A., Friend, K., Arisa, O. T., Figg, W. D., Fink, D., Kuhns, D. B., Colton, B., Peer, C. J., & Goldbach-Mansky, R. (2025). Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING‐Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy. Arthritis & Rheumatology, 77(8), 1087-1091. https://doi.org/10.1002/art.43145
Vancouver
Alehashemi S, Buehring B, de Jesus AA, Gaurav S, Rastegar A, Baumgardner A, et al. Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING‐Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy. Arthritis & Rheumatology. 2025;77(8):1087-1091. doi:10.1002/art.43145
BibTeX
@article{Alehashemi2025,
author = {Alehashemi, Sara and Buehring, Bjoern and de Jesus, Adriana A and Gaurav, Sachin and Rastegar, Andre and Baumgardner, Alexi and Friend, Kip and Arisa, Oluwatobi T and Figg, William D and Fink, Danielle and Kuhns, Douglas B and Colton, Ben and Peer, Cody J and Goldbach-Mansky, Raphaela},
title = {Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING‐Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy},
journal = {Arthritis & Rheumatology},
year = {2025},
volume = {77},
number = {8},
pages = {1087--1091},
doi = {10.1002/art.43145}
}
EUVIMED